By Fineline Cube 
Shanghai-based biotech EpimAb Biotherapeutics, Inc. has submitted a main board listing application to the Hong Kong Stock Exchange. CITIC Securities and CMB International are acting as joint sponsors for the IPO.
Company Overview
Founded in 2015, EpimAb is a clinical-stage biotech specializing in bispecific antibody therapeutics. The company focuses on T-cell engagers (TCEs) for cancer and autoimmune diseases. It has three clinical-stage drug candidates, including its core asset EMB-01 (EGFR/cMET) for colorectal cancer, and EMB-06 (BCMA/CD3) and EMB-07 (ROR1/CD3) for multiple myeloma and lymphoma/solid tumors. EM1032 (ALPP(G)/CD3), EM1034 (LY6G6D/CD3), and EM1031 (KLK2/CD3) are TCE drug candidates in preclinical stages. Its immunology pipeline includes clinical-stage EMB-06 and preclinical TCEs EM1039 and EM1042.
Financial Performance
In 2024, EpimAb achieved profitability for the first time, generating RMB 459 million in revenues and RMB 47.69 million in net profits.-Fineline Info & Tech